Impact of anticholinergics on the aging brain: A review and practical application

Aging Health

Volumn 4, Issue 3, 2008, Pages 311-320

  Boustani, Malaz ^a,c   Campbell, Noll ^b   Munger, Stephanie ^a,c   Maidment, Ian ^d   Fox, Chris ^e  

^a REGENSTRIEF INSTITUTE   (United States)

^b WISHARD HEALTH SERVICES   (United States)

^c INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^d KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^e Fokestone Health Centre   (United Kingdom)

Author keywords

Anticholinergic activity; Cognitive impairment; Delirium; Dementia; Elderly; Prescribing

Indexed keywords

AMANTADINE; AMITRIPTYLINE; AMOXAPINE; ATROPINE; BELLADONNA ALKALOID; BENZATROPINE; BROMPHENIRAMINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; COCODAMOL; CYCLOBENZAPRINE; CYPROHEPTADINE; DIPHENHYDRAMINE; DONEPEZIL; HALOPERIDOL; IPRATROPIUM BROMIDE; LEVOMEPROMAZINE; LOXAPINE; MOLINDONE; NON PRESCRIPTION DRUG; OLANZAPINE; OXCARBAZEPINE; OXYBUTYNIN; PETHIDINE; PIMOZIDE; SCOPOLAMINE; TRAZODONE; UNINDEXED DRUG;

AGED; AGING; ALZHEIMER DISEASE; AMNESIA; ANAMNESIS; ANTICHOLINERGIC COGNITIVE BURDEN SCALE; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC RISK SCALE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BINDING AFFINITY; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION ASSESSMENT METHOD; CONSTIPATION; DELIRIUM; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG USE; DRUG WITHDRAWAL; EXPERT BASED DRUG LIST; GERIATRIC ASSESSMENT; GERIATRIC CARE; HALLUCINATION; HUMAN; INSOMNIA; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; NEUROTOXICITY; PARKINSON DISEASE; PATIENT SAFETY; PRACTICE GUIDELINE; PREVALENCE; RADIORECEPTOR ASSAY; REVIEW; RISK FACTOR; SERUM RADIORECEPTOR ANTICHOLINERGIC ACTIVITY ASSAY; SIDE EFFECT; TACHYCARDIA; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

EID: 48249104393     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.4.3.311     Document Type: Review

References (45)

1. Vangala VR, Tueth MJ: Chronic anticholinergic toxicity: identification and management in older patients. Geriatrics 358, 36-37 (2002).
2. Roe C, Anderson M, Spivack B: Use of anticholinergic medications by older adults with dementia. J. Am. Geriatr. Soc. 50, 836-842 (2002).
3. Flacker JM, Virginia C, Mach JR, Bettin K, Kiely DK, Wei J: The association of serum anticholinergic activity with delirium in elderly medical patients. Am. J. Geriatr. Psychiatry 6, 31-41 (1998).
4. Blazer DG 2nd, Federspiel CF, Ray WA, Schaffner W: The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J. Gerontol. 38, 31-35 (1983).
5. Mulsant BH, Pollock BG, Kirshner M, Shen C, Hiroko D, Ganguli M: Serum anticholinergic activity in a community-based sample of older adults. Arch. Gen. Psychiatry 60, 198-203 (2003).
6. Tune LE: Anticholinergic effects of medication in elderly patients. J. Clin. Psychiatry 62(Suppl. 21), 11-14 (2001).
7. Dyer CB, Ashton C, Teasdale TA: Postoperative delirium: a review of 80 primary data-collection studies. Arch. Intern. Med. 155(5), 461-465 (1995).
8. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disordeis (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
9. Boustani M, Buttar A: Delirium. In: Primary Care Geriatrics, a Case-Based Approach (5th Edition). Ham RJ, Sloane PD, Warshaw GA, Bernard MA, Flaherty E (Eds). Chapter 15, 210-218 (2007).
10. Boustani M, Ham RJ: Alzheimer disease and other dementias. In: Primary Care Geriatrics, a Case-Based Approach (5th Edition). Ham RJ, Sloane PD, Warshaw GA, Bernard MA, Flaherty E (Eds). Chapter 16, 219-236 (2007).
11. Boustani M, Schubert C, Sennour Y: The challenge of supporting care for dementia in primary care. Clin. Interv. Aging 2(4), 631-636 (2007).
12. Boustani M, Peterson B, Hanson L et al.: Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 138(11), 927-937 (2003).
13. Boustani M, Callahan CM, Unverzagt FW et al.: Implementing a screening and diagnosis program for dementia in primary care. J. Gen. Intern. Med. 20(7), 572-577 (2005).
14. Ferri CP, Prince M, Brayne C et al.: Alzheimer's disease international. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503), 2112-2117 (2005).
15. The Lewin Group: Saving lives. Saving money: dividends for Americans investing in Alzheimer research. Report of the Lewin Group to the Alzheimer's Association (2004).
16. DeKosky ST: Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J. Am. Geriatr. Soc. 51(5 Suppl. Dementia), S314-S320 (2003).
17. Terry AV Jr, Buccafusco JJ: The cholinergic hypothesis of age and alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306(3), 821-827 (2003).
18. Sivaprakasam K: Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr. Med. Chem. 13(18), 2179-2188 (2006).
19. Cummings JL: Cholinesterase, inhibitors: a new class of psychotropic compounds. Am. J. Psych. 157(1), 4-15 (2000).
20. Sperling R, Greve D, Dale A et al.: Functional MRI detection of pharmacologically induced memory impairment. Proc. Natl. Acad. Sci. USA 99, 455-460 (2002).
21. Flicker C, Serby M, Ferris SH: Scopolamine effects on memory language, visuospatial praxis and psychomotor speed. Psychopharmacology (Berl.) 100, 243-250 (1990).
22. Flicker C, Ferris SH, Serby M: Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl.) 107, 437-441 (1992).
23. Drachman DA, Noffsinger D, Sahakian BJ, Kurdziel S, Fleming P: Aging, memory, and the cholinergic system: a study of dichotic listening. Neurobiol. Aging 1, 39-43 (1980).
24. Chew ML, Musant BH, Pollock BG: Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am. J. Geriatr. Psychiatry 13, 5354-5538 (2005).
25. Shepherd G, Klein-Schwartz W, Edwards R: Donepezil overdose: a tenfold dosing error. Ann. Pharmacother. 33, 812-815 (1999).
26. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH: Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic, drugs. Ann. Neurol. 54, 235-238 (2003).
27. Rudd KM, Raehl CL, Bond CA, Abbruscato TJ, Stenhouse AC: Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 25, 1592-1601 (2005).
28. Tollefson GD, Montague-Clouse J: The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J. Neuropsychiatry Clin. Neurosci. 3(3), 314-319 (1991).
29. Tune L, Carr S, Hoag E, Cooper T: Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am. J. Psychiatry 149, 1393-1394 (1992).
30. Schubert CC, Boustani M, Callahan CM et al.: Comorbidity profile of dementia patients in primary care: are they sicker? J. Am. Geriatr. Soc. 54(1), 104-109 (2006).
31. Ancellin ML, Artero S, Portet F, Dupuy AM, Touchon J, Rithie K: Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Br. Med. J. 332(7539), 455-459 (2006).
32. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR: The anticholinergic drug scale as a measure of drug-related anticholinergic burden: association with serum anticholinergic activity. J. Clin. Pharmacol. 46, 1481-1486 (2006).
33. Tune L, Coyle JT: Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch. Gen. Psychiatry 37, 293-297 (1980).
34. Moore AR, O'Keeffe ST: Drug-induced cognitive impairment in the elderly. Drugs Aging 15, 15-28 (1999).
35. Francis J: A half-century of delirium research: time to close the gap. J. Am. Geriatr. Soc. 43, 585-586 (1995).
36. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M: Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch. Intern. Med. 161, 1099-1105 (2001).
37. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch. Intern. Med. 163, 2716-2724 (2003).
38. Feinberg M: The problems of anticholinergic adverse effects in older patients. Drugs Aging 3, 335-348 (1993).
39. Basu R, Dodge H, Stoehr GP, Ganguli M: Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am. J. Geriatr. Psychiatry 11, 205-213 (2003).
40. Tune L, Coyle JT: Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 75, 9-15 (1981).
41. Boustani MA, Limbil T, Campbell N, Fox C, Maidment I: Anticholinergic burden: measurement and impact. J. Am. Geriatr. Soc. 55, S52 (2007).
42. Bottigi KA, Salazar JC, Yu L et al.: Long-term cognitive impact of anticholinergic medications in older adults. Am. J. Geriatr. Psychiatry 14(11), 980-984 (2006).
43. Lim CJ, Trevino C, Tampi RR: Can olanzapine cause delirium in the elderly? Ann. Pharmacother. 40, 135-138 (2006).
44. deLion J: Letter to the editor. Benztropine equivalents for antimuscarinic medication. Am. J. Psychiatry 162, 627 (2005).
45. Rudolph JL, Sallow MJ, Angelini MC, McGlinchey RE: The anticholinergic risk scale and anticholinergic adverse effects in older adults. Arch. Intern. Med. 168, 508-513 (2008).